Healthcare · NIFTY 500

Cohance Lifesciences Limited

NSECOHANCE BSE543064 ISININE03QK01018 SeriesEQ Listed on NSE · BSE

₹471.65 +7.55 (+1.63%) Updated 12 Nov, 8:49 pm IST

Open chart Back to screener

Price, daily close-41.63% in a year

Today

Open: ₹463.30
Prev close: ₹464.10
Day high: ₹474.00
Day low: ₹457.30
Volume: 5.03 L
Value traded: ₹23.46 Cr
Upper circuit: ₹556.90
Lower circuit: ₹371.30
52W high: ₹748.95
52W low: ₹266.70
1 month: -2.00%
6 months: -9.48%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹18,045 Cr

P/E (TTM)396.34

P/B4.61

Book value / share₹102.25

EPS (TTM)₹1.19

ROE1.2%

Dividend yield—

Dividend (12m)—

Net margin (TTM)2.3%

Operating margin7.4%

Debt / equity0.06

Current ratio1.98

EV / EBITDA86.88

Sales growth (YoY qtr)-14.21%

Profit growth (YoY qtr)-79.45%

Sales CAGR 3Y+19.17%

Profit CAGR 3Y-24.19%

Shares38.26 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

22046.8

Dec 23

2530.0

Mar 24

2310.0

Jun 24

25882.2

Sep 24

30782.9

Dec 24

40242.0

Mar 25

54948.9

Jun 25

55674.1

Sep 25

54536.7

Dec 25

61919.6

Mar 26

422-24.1

Jun 26

47715.2

Sep 26

Revenue · QoQ (vs last quarter)

—+15%-8.8%+12%+19%+31%+37%+1.1%-2.0%+14%-32%+13%

Revenue · YoY (vs a year ago)

————+40%+59%+138%+116%+77%+54%-23%-14%

Net profit · QoQ (vs last quarter)

—-100%——+0.8%-49%+16%+52%-50%-47%-223%+163%

Net profit · YoY (vs a year ago)

————+77%——-9.9%-56%-53%-149%-79%

RevenueNet profitLine = trend

1.84

Dec 23

2.10

Mar 24

2.39

Jun 24

3.21

Sep 24

3.23

Dec 24

1.59

Mar 25

1.27

Jun 25

1.93

Sep 25

0.96

Dec 25

0.50

Mar 26

-0.65

Jun 26

0.38

Sep 26

EPS (₹) · YoY (vs a year ago)

————+76%-24%-47%-40%-70%-69%-151%-80%

EPS (₹)Line = trend

₹ Cr	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	220	253	231	258	307	402	549	556	545	619	422	477
Other income	14.3	17.1	18.2	14.1	15.7	10.6	14.2	15.6	6.2	-1.8	12.3	12.4
Total income	234	270	249	272	323	413	563	571	551	617	435	489
Raw material	63.5	71.4	38.3	47.1	67.0	70.2	178	192	197	139	159	237
Purchases	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Employee cost	32.8	39.4	45.6	51.9	63.3	89.1	133	127	119	129	133	154
Other expenses	49.4	56.5	41.5	49.8	70.5	105	156	167	172	177	168	149
Total expenses	169	199	166	172	213	361	493	487	505	581	477	500
Operating profit	65.1	73.3	79.9	104	118	73.6	104	121	90.5	82.2	1.2	35.4
OPM %	29.6%	29.0%	34.6%	40.4%	38.3%	18.3%	18.9%	21.8%	16.6%	13.3%	0.3%	7.4%
Finance cost	1.3	2.3	1.6	1.7	3.3	5.8	10.2	8.8	9.1	9.2	6.7	8.4
Depreciation	12.8	17.2	13.4	17.0	20.4	26.8	45.1	44.0	46.9	51.2	49.5	50.2
Exceptional items	—	—	—	—	—	—	-8.1	—	-4.9	-16.5	—	—
Profit before tax	65.5	70.9	83.1	99.5	110	51.6	62.8	83.8	40.6	19.9	-42.9	-10.8
Tax	18.7	17.5	22.3	17.5	26.4	12.9	16.4	17.4	11.6	11.6	2.3	-13.0
Net profit	46.8	53.4	60.8	82.0	83.3	38.7	46.4	66.4	29.0	8.3	-45.2	2.3
Profit to shareholders	—	0.0	0.0	82.2	82.9	42.0	48.9	74.1	36.7	19.6	-24.1	15.2
EPS (₹)	1.84	2.10	2.39	3.21	3.23	1.59	1.27	1.93	0.96	0.50	-0.65	0.38

Profit & loss

Results for each year

7 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

834385317

FY20

1,010440362

FY21

1,3205790.0

FY22

1,340567411

FY23

1,0514060.0

FY24

1,198375268

FY25

2,269398179

FY26

Revenue · YoY (vs a year ago)

—+21%+31%+1.5%-22%+14%+89%

Net profit · YoY (vs a year ago)

—+14%-100%—-100%—-33%

RevenueOperating profitNet profitLine = trend

₹ Cr	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	834	1,010	1,320	1,340	1,051	1,198	2,269
Other income	18.1	14.2	92.4	46.4	61.9	58.6	34.1
Total expenses	496	610	786	827	708	912	2,066
Employee cost	73.7	76.2	100	111	136	250	508
Operating profit	385	440	579	567	406	375	398
OPM %	46.2%	43.6%	43.9%	42.3%	38.6%	31.3%	17.5%
Finance cost	23.1	9.1	6.2	5.4	7.5	12.4	37.2
Depreciation	23.9	31.6	39.1	47.7	54.6	77.5	187
Profit before tax	356	414	626	560	406	344	207
Tax	87.5	105	214	148	105	79.2	56.9
Tax rate %	24.6%	25.4%	34.1%	26.5%	26.0%	23.0%	27.5%
Net profit	317	362	454	411	300	265	150
Profit to shareholders	—	—	0.0	—	0.0	268	179
Net margin %	38.0%	35.9%	0.0%	30.7%	0.0%	22.4%	7.9%
EPS (₹)	24.91	14.23	17.83	16.16	11.80	10.45	4.68

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

1,73569.264.8

Mar 23

2,05138.647.2

Mar 24

1,69778.185.4

Mar 25

3,91117049.1

Mar 26

3,91222898.6

Sep 26

Shareholders' equity · YoY (vs a year ago)

—+18%-17%+131%—

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26	Sep 26
Shareholders' equity	1,735	2,051	1,697	3,911	3,912
Long-term borrowings	4.6	0.0	6.2	50.5	28.1
Short-term borrowings	64.6	38.6	71.9	119	200
Total borrowings	69.2	38.6	78.1	170	228
Current liabilities	159	107	365	646	865
Fixed assets (PPE)	584	567	995	1,990	1,727
Inventories	313	231	167	562	734
Trade receivables	111	134	284	681	469
Cash & equivalents	64.8	47.2	85.4	49.1	98.6
Current assets	1,011	1,263	853	1,796	1,717
Total assets	1,966	2,254	3,032	5,730	5,680
Debt / equity	0.04	0.02	0.05	0.04	0.06

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

330-136-156

FY22

451-195-236

FY23

358-362-13.8

FY24

288-2553.3

FY25

368-255-165

FY26

Operations · YoY (vs a year ago)

—+37%-20%-20%+28%

OperationsInvestingFinancingLine = trend

₹ Cr	FY22	FY23	FY24	FY25	FY26
Cash from operations	330	451	358	288	368
Cash from investing	-136	-195	-362	-255	-255
Cash from financing	-156	-236	-13.8	3.3	-165
Spent on fixed assets	-75.2	-286	-51.8	-156	-220
Free cash flow	255	165	307	132	148
Net cash flow	37.4	20.2	-17.6	36.2	-51.4

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

50.1%Mar 24

50.1%Jun 24

50.1%Sep 24

50.1%Dec 24

50.1%Mar 25

66.4%May 25

66.4%Jun 25

57.5%Sep 25

57.5%Dec 25

57.5%Mar 26

57.5%Jun 26

57.5%Sep 26

Promoter & groupPublic

Latest (30 Sep 2026)

57.5%promoter

Promoter & group: 57.48%
Public (FIIs, mutual funds, retail…): 42.52%
Promoter change, last quarter: -0.01 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Annual General MeetingEx 06-Aug-2024
Annual General MeetingEx 12-Dec-2023
Interim Dividend - Re 1 Per Share/Special Dividend- Rs 5 Per ShareEx 09-Sep-2022
Annual General MeetingEx 11-Aug-2022
Interim Dividend - Re 1 Per Share/Special Dividend - Re 1 Per ShareEx 13-May-2022
Interim Dividend - Re 1 Per Share/ Special Dividend - Rs 2 Per ShareEx 15-Feb-2022
Annual General Meeting/Dividend - Re 1 Per ShareEx 13-Aug-2021
Interim Dividend - Re 1 Per ShareEx 17-Feb-2021

Board meetings

Cohance Lifesciences Limited has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited…06-Nov-2026
the financial results for the period ended September 30, 202606-Nov-2026
Cohance Lifesciences Limited has informed the Exchange about Board Meeting to be held on 05-Aug-2026 to inter-alia consider and approve the Unaudited…05-Aug-2026
the financial results for the period ended Jun 30, 202605-Aug-2026
Cohance Lifesciences Limited has informed the Exchange about Board Meeting to be held on 12-May-2026 to inter-alia consider and approve the Audited F…12-May-2026

Filings with NSE

Analysts/Institutional Investor Meet/Con. Call Updates11 Nov
Analysts/Institutional Investor Meet/Con. Call Updates11 Nov
Investor Presentation7 Nov
Copy of Newspaper Publication7 Nov
General Updates7 Nov
Analysts/Institutional Investor Meet/Con. Call Updates7 Nov
Press Release6 Nov

Latest news

Cohance Lifesciences Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearSimply Wall St · 10 Nov, 5:56 am Cohance Lifesciences share price surges 37% in two days on appointment of new CEOLivemint · 28 Apr, 12:30 pm Cohance Lifesciences Stock Jumps Over 2% Despite Poor Q1 Earnings; Here's WhyNDTV Profit · 6 Aug, 12:30 pm Cohance Lifesciences shares slip 7% after Jefferies cuts target price, downgrades on weak Q4The Economic Times · 13 May, 12:30 pm Why Cohance Lifesciences Share Price is RisingEquitymaster · 23 Jun, 12:30 pm Stocks to Watch Today: Tata Steel, Data Patterns, Voltas, Aster DM, GE Shipping, Gland Pharma, Finolex...Moneycontrol.com · 8 Nov, 11:01 am Up nearly 40% in 2 days: What's fuelling this pharma stock's rallyIndia Today · 28 Apr, 12:30 pm Cohance Lifesciences receives central government approval for Umang Vohrascanx.trade · 12 Oct, 12:30 pm

About

About Cohance Lifesciences Limited

Cohance Lifesciences Limited is listed on the NSE under the symbol COHANCE and belongs to the Healthcare sector.

Company details

Company name: Cohance Lifesciences Limited
NSE symbol: COHANCE
BSE scrip code: 543064
ISIN: INE03QK01018
Listed on: NSE, BSE
Series: EQ (normal equity)
Listed on NSE since: 9 Mar 2020
Face value: ₹1 per share
Market lot: 1 share
Shares issued: 38.26 crore
Index: NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Major
Managing director / CEO: Umang Vohra
Chair: Umang Vohra
Headquarters: Hyderabad, Telangana, India
Founded: 2018
Employees: 5,051
Financial year: April to March
Results basis: Consolidated
Website: cohance.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Cohance Lifesciences Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Sep 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers